onc Videos

Videos

Videos

Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL

09/05/2023

Featuring Kami J. Maddocks, MD

Featuring Kami J. Maddocks, MD ...

Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.

Kami J. Maddocks, MD, analyzes...

09/05/2023

Oncology

Videos

Exploring Mechanisms and Approaches for Graft-Versus-Host Disease Prophylaxis

09/05/2023

Featuring Ernst Holler, MD

Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Analyzing Risk Factors for Acute and Chronic Graft-Versus-Host Disease

09/05/2023

Featuring Ernst Holler, MD

Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Antibody Drug Conjugates for the Frontline Treatment of Patients With Advanced-Stage Hodgkin Lymphoma

09/05/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...

Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...

Andrew Evens, DO, MBA, MSc,...

09/05/2023

Oncology

Videos

Promising Outcomes of FGFR1 Inhibitor Pemigatinib for Myeloid Lymphoid Neoplasms

08/28/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...

Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Daniel DeAngelo, MD, PhD,...

08/28/2023

Oncology

Shinichi Nishina, MD, Kurashiki Central Hospital

Videos

RAS Status in ctDNA After Chemotherapy Among Patients With RAS-Mutant Colorectal Cancer

08/28/2023

Featuring Shinichi Nishina, MD

Featuring Shinichi Nishina, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Shinichi Nishina, MD, reported data on that RAS status in ctDNA of patients with RAS-mutant metastatic colorectal cancer who responded to first- or second-line chemotherapy.

At the 2023 World Congress on...

08/28/2023

Oncology

Videos

Increasing Incidence of Early-Onset Colorectal Cancer

08/28/2023

Featuring Irit Ben-Aharon, MD, PhD

Featuring Irit Ben-Aharon, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Irit Ben-Aharon, MD, PhD discussed how the incidence of early-onset colorectal cancer has risen over the past 2 decades.

At the 2023 World Congress on...

08/28/2023

Oncology

Florence Huguet, MD, PhD, Tenon Hospital at Sorbonne University in Paris

Videos

The Role of Radiation Therapy in Treating Locally Advanced Pancreatic Cancer

08/28/2023

Featuring Florence Huguet, MD, PhD

Featuring Florence Huguet, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Florence Huguet, MD, PhD, debated in favor of radiation therapy being used in the treatment of locally advanced pancreatic cancer.

At the 2023 World Congress on...

08/28/2023

Oncology

Videos

Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

08/28/2023

Featuring Stefan Knop, MD

Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.

Stefan Knop, MD, presents...

08/28/2023

Oncology

Videos

Examining CD38-Targeting Antibody Therapies for Patients With Newly Diagnosed Transplant-Ineligible Multiple Myeloma

08/28/2023

Featuring Peter Voorhees, MD

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.

At the 2023 Great Debates &...

08/28/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology